title: Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner.
authors.forename: Charlotte L
authors.initials: CL
authors.lastname: Krieckaert
authors.forename: Michael T
authors.initials: MT
authors.lastname: Nurmohamed
authors.forename: Gerrit Jan
authors.initials: GJ
authors.lastname: Wolbink
mesh_terms: D000068879:Adalimumab; D000888:Antibodies, Anti-Idiotypic / Q000097:blood / Q000187:drug effects / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000276:immunology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D055261:Immunogenetic Phenomena / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008727:Methotrexate / Q000494:pharmacology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000068879:Adalimumab; D008727:Methotrexate